Form 4: BDX Executive Michael Garrison Sells Shares

Becton Dickinson EVP Michael Garrison sold 1,100 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael David Garrison, EVP & President of Med. Essntl & BioPharm at Becton Dickinson, sold 1,100 shares of common stock.
• The transaction occurred on June 10, 2026, at a price of $151.48 per share.
• Following the sale, the reporting person maintains direct ownership of 14,272 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 18, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 arrangement, which is standard practice for corporate officers.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance activities and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at large-cap medical technology firms like Becton Dickinson to manage personal liquidity.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• None mentioned.

Key Dates

Keywords

BDX, Becton Dickinson, Insider Trading, Form 4, Executive Compensation, Rule 10b5-1